10x Genomics Inc
For the period ended Dec 31, 2023. Filed Feb 15, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 15, 2024
TXG$65.05+9.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
(In thousands, except share and per share data)
| Year Ended December 31, | |||
|---|---|---|---|
| 2023 | 2022 | 2021 | |
| Revenue | $618,727 | $516,409 | $490,490 |
| Cost of revenue | 209,414 | 120,386 | 74,091 |
| Gross profit | 409,313 | 396,023 | 416,399 |
| Operating expenses: | |||
| Research and development | 270,332 | 265,667 | 211,752 |
| In-process research and development | 60,980 | — | — |
| Selling, general and administrative | 343,330 | 298,300 | 257,560 |
| Accrued contingent liabilities | — | — | (660) |
| Total operating expenses | 674,642 | 563,967 | 468,652 |
| Loss from operations | (265,329) | (167,944) | (52,253) |
| Other income (expense): | |||
| Interest income | 16,906 | 6,647 | 206 |
| Interest expense | (33) | (476) | (866) |
| Other expense, net | (307) | (198) | (802) |
| Total other income (expense) | 16,566 | 5,973 | (1,462) |
| Loss before provision for income taxes | (248,763) | (161,971) | (53,715) |
| Provision for income taxes | 6,336 | 4,029 | 4,508 |
| Net loss | $(255,099) | $(166,000) | $(58,223) |
| Net loss per share, basic and diluted | $(2.18) | $(1.46) | $(0.53) |
| Weighted-average shares used to compute net loss per share, basic and diluted | 117,165,036 | 113,858,684 | 110,347,937 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.